Predicted loss of function variants in BRCA1 and BRCA2 were present at increased frequencies in individuals with a breast cancer diagnosis and ovary as an additional cancer site (Fig. 3), such that 28.6% and 13.6% of individuals, respectively, were a carrier for at least one variant in the burden set. This evidence concerns the gene BRCA2 and cancer.